Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Jeay S, Ferretti S, Holzer P, Fuchs J, Chapeau EA, Wartmann M, Sterker D, Romanet V, Murakami M, Kerr G, Durand EY, Gaulis S, Cortes-Cros M, Ruetz S, Stachyra TM, Kallen J, Furet P, W├╝rthner J, Guerreiro N, Halilovic E, Jullion A, Kauffmann A, Kuriakose E, Wiesmann M, Jensen MR, Hofmann F, Sellers WR.

Cancer Res. 2018 Nov 1;78(21):6257-6267. doi: 10.1158/0008-5472.CAN-18-0338. Epub 2018 Aug 22.

PMID:
30135191
2.

Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.

Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, Jose J, Oliver R.

Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi: 10.1002/cpdd.121. Epub 2014 May 26.

PMID:
27129012
3.

Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab.

Kretsos K, Jullion A, Zamacona M, Harari O, Shaw S, Boulanger B, Oliver R.

CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3:e119. doi: 10.1038/psp.2014.17.

4.

Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.

Jullion A, Lambert P, Beck B, Vandenhende F.

Pharm Stat. 2009 Apr-Jun;8(2):98-112. doi: 10.1002/pst.336.

PMID:
18481279

Supplemental Content

Loading ...
Support Center